ASH2023 - Sheba 2.0, page-71

Hi @Davisite. Great to see positive results from this trial. As if we ever doubted!

In regards to Q&A, I have the following suggestions for things I would like to see addressed (in addition to input others have already provided):
1) What are the potential implications for Race of the results of this trial in establishing Bisantrene as a commercially viable/appealing treatment for AML? Do the results of this trial help in any way to accelerate the timeline for getting Bisantrene to people who can benefit from it?
2) Although this trial was directed towards salvage treatment for heavily pre-treated patients, does it help to provide a path for Bisantrene to move up the value chain towards being an earlier stage treatment option in future trials?
3) Only the abstract has been released so far. Will there will be additional detail and information in the poster and/or presentation? If so, what sort of additional information can we expect to find out and what value may come from this?
4) Should we expect to hear additional information on the outcomes of this trial in future and what format might that take if so?
- This abstract appears to have been written prior to recruitment of the final two patients mentioned in the strategic update - will there be further updates when the trial has completed recruitment?
- Will the patients continue to be followed up and will there be future updates on longer term survivability?
- Can we expect future updates on any other secondary data that may or may not have been collected during this trial (FTO, Cardioprotection, etc.)?
5) What plans does Race have regarding the recommendations for future combination trials (Venetoclax and/or hypomethylating agents)?
6) What plans does Race have for future collaboration and/or trials with Prof Nagler's team given the success of the relationship so far and their obvious enthusiasm for seeing Bisantrene succeed?

Thanks in advance and enjoy your weekend.